Companies: 10,795·Total market cap: $144.5T
Connect Biopharma Holdings Limited

Connect Biopharma Holdings Limited

CNTBNASDAQHealthcare● Active
$2.20
+$0.03(+1.38%)
Market Cap$138520477
P/E Ratio
52W High$3.82
52W Low$0.753

Connect Biopharma Holdings Limited (CNTB) PE Ratio — Current & Historical Data

Trailing twelve months (TTM) P/E, forward P/E, PEG, and annual PE history — from market prices and filings.

cntb · pe ratio · data through Dec 31, 2025

Core PE Ratio Metrics

Trailing 12 months · TTM

The price-to-earnings (P/E) ratio for Connect Biopharma Holdings Limited (CNTB) measures how much investors pay for each dollar of the company's trailing earnings. CNTB's current PE ratio of N/A is calculated by dividing its stock price of $2.20 by its TTM earnings per share of -$0.50.

N/A
P/E Ratio (TTM)N/A — Company is not profitable (TTM)

Source: FMP · /ratios-ttm · /analyst-estimates · 2025-12-31

Forward P/E
N/A
FY2027 est. EPS $-1.05
Based on 5 analysts
EPS (TTM)
-$0.50
TTM · diluted EPS
PEG Ratio
0.03
Below 1.0 · Growth adjusted
Source: FMP · /ratios-ttm · /ratios annual · /analyst-estimates · /stock-peers · Connect Biopharma Holdings Limited SEC 10-K & 10-Q filings · US GAAPUpdated: 2026-06-08

PE Ratio History

2018 – 2025 · Annual
PE Ratio (TTM)
EPS (Annual)

▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare (Annual)

PE Ratio vs Peers

Biotechnology · 6 peers · Annual PE
CompanyMarket CapPE (Annual)vs AvgEPS (TTM)
Connect Biopharma Holdings Limited
Connect Biopharma Holdings LimitedYou
CNTB
$139MN/A-$0.50
Artiva Biotherapeutics, Inc.
Artiva Biotherapeutics, Inc.
ARTV
$168MN/A-$3.43
Context Therapeutics Inc.
Context Therapeutics Inc.
CNTX
$157MN/A-$0.38
InflaRx N.V.
InflaRx N.V.
IFRX
$124MN/A-$0.68
ImageneBio Inc
ImageneBio Inc
IMA
$64MN/A-$9.31
Kalaris Therapeutics Inc
Kalaris Therapeutics Inc
KLRS
$78MN/A-$2.85
Metagenomi, Inc. Common Stock
Metagenomi, Inc. Common Stock
MGX
$49MN/A-$2.36

* N/A — Company is not profitable (TTM) · excluded from industry average · ▸ FMP /stock-peers + /ratios?limit=1 · priceToEarningsRatio

Annual PE Ratio History

Showing 8 of 8 years
Fiscal Year EndPE RatioEPS (TTM)YoY ChangePE vs Max
2025-12-31Latest
FY2025
$-1.00
2024-12-31
FY2024
$-0.28
2023-12-31
FY2023
$-1.13
2022-12-31
FY2022
$-2.15
2021-12-31
FY2021
$-3.87
2020-12-31
FY2020
$-2.21
2019-12-31
FY2019
$-0.44
2018-12-31
FY2018
$0.00

▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare · Zero extra API

About PE Ratio & Methodology

The price-to-earnings (P/E) ratio for Connect Biopharma Holdings Limited (CNTB) measures how much investors pay for each dollar of the company's trailing earnings. CNTB's current PE ratio of N/A is calculated by dividing its stock price of $2.20 by its TTM earnings per share of -$0.50.

PE Ratio = Stock Price ÷ EPS (TTM)
= $2.20 ÷ -$0.50 = N/A
TTMTrailing Twelve Months — sum of the most recent 4 quarterly EPS figures
Forward PEStock price ÷ analyst consensus EPS estimate for the next fiscal year
PEGPE ÷ earnings growth rate — values below 1.0 suggest growth may justify the premium
Figures tie to SEC 10-K/10-Q and FMP ratio endpoints where noted.

Frequently asked questions

CNTB pe ratio · 6 questions

CNTB's current PE ratio is N/A as of 2026-06-08, based on a stock price of $2.20 and TTM EPS of -$0.50. Data sourced from Financial Modeling Prep via CNTB's SEC 10-K and 10-Q filings.

CNTB PE ratioWhat is CNTB PE ratioCurrent PE ratio of CNTBCNTB PE ratio today

Source: FMP · /ratios-ttm · /ratios annual · /analyst-estimates · /stock-peers · Connect Biopharma Holdings Limited SEC 10-K & 10-Q filings · US GAAP · Updated: 2026-06-08